Adam Pennycuick
@adampennycuick.bsky.social
Lung Oncologist @UCLH | Bioinformatician @lungsforliving | Founder @oslrapp researchbriefing.com | Early lung cancer, prevention, MedEd, all things data 👨💻
But previous neoadj osimertinib trial declared a failure due to low MPR rate buff.ly/AAyHQO1. Similar MPR rates in both. Good lesson to focus on the endpoint that matters most. Both found with researchbriefing.com
April 7, 2025 at 8:00 AM
But previous neoadj osimertinib trial declared a failure due to low MPR rate buff.ly/AAyHQO1. Similar MPR rates in both. Good lesson to focus on the endpoint that matters most. Both found with researchbriefing.com